Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...

Cutting down on sodium when you have IgAN can help preserve your kidney function. Learn ways to drop salt without forgetting about flavor.

LAS VEGAS, NV / ACCESS Newswire / February 26, 2026 / Cytta Corp. (OTCQB:CYCA) today announced plans to transfer the CyttaCOMMS intellectual property into IGAN ™ Corp, its wholly owned Special Purpose ...

Novartis recently announced positive final results from the Phase III APPLAUSE-IgAN clinical trial. The final results from the APPLAUSE-IgAN Phase III trial demonstrate that Fabhalta (iptacopan) ...

IgA nephropathy, an immune assault on the kidneys, is often missed. New treatments mean that spotting it sooner might save ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.

For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with maximally titrated irbesartan had slower decline in kidney function. Patients treated with ...

A past or present diagnosis of inflammatory bowel disease elevates the risk of progression to kidney failure among patients with IgA nephropathy, according to investigators. Inflammatory bowel disease ...

The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...